Can better prescribing turn the tide of resistance?

Nature Reviews Microbiology

Volumn 2, Issue 1, 2004, Pages 73-78

  Livermore, David ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AVOPARCIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; ERYTHROMYCIN; GARENOXACIN; GEMIFLOXACIN; IMIPENEM; LINEZOLID; MOXIFLOXACIN; ORITAVANCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; SULFONAMIDE; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYSTITIS; ESCHERICHIA COLI; HUMAN; INFECTION RISK; MEDICAL PRACTICE; NATIONAL HEALTH SERVICE; NEISSERIA GONORRHOEAE; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; STAPHYLOCOCCUS INFECTION; UNITED KINGDOM; UNITED STATES; BACTERIUM; CLINICAL PRACTICE; DRUG EFFECT; MICROBIOLOGY; REVIEW;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEISSERIA; NEISSERIA GONORRHOEAE; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 1842591127     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro798     Document Type: Article

References (53)

1. Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J. & Kollef, M. H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118, 146-155 (2000).
2. Report of the Joint Committee on the Use of Antimicrobials in Animal Husbandry and Veterinary Medicine. (Her Majesty's Stationery Office, UK, 1969).
3. House of Lords Select Committee on Science and Technology Seventh Report. Resistance to Antibiotics and other Antimicrobial Agents. (Her Majesty's Stationery Office, UK, 1998).
4. UK Standing Medical Advisory Committee (SMAC). The Path of Least Resistance. (Department of Health, UK, 1998).
5. WHO Global Strategy for Containment of Antimicrobial Resistance. (World Health Organization, Geneva, 2001).
6. Opinion of the Scientific Steering Committee on Antimicrobial Resistance. (European Commission, 2003).
7. Interagency Task Force on Antimicrobial Resistance. [online], (cited 20 Nov 2003), (2001).
8. Livermore, D. M. Bacteria] resistance: origins, epidemiology, and impact. Clin. Infect. Dis. 36, S11-S23 (2003).
9. McCaig, L. F., Besser, R. E. & Hughes, J. M. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg. Infect. Dis. 9, 432-437 (2003).
10. Livermore, D. M. et al. Trends in fluoroquinolone (ciprofloxacin) resistance among Enterobacteriaceae from bacteraemias h England and Wales, 1990-1999. Emerg. Infect. Dis. 8, 473-478 (2002).
11. Fenton, K. A. et al. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. Lancet 361, 1867-1869 (2003).
12. Staphylococcus aureus with reduced susceptibility to vancomycin. CDR Weekly 12, 2-3 [online], (cited 20 Nov 2003), (17 May 2002).
13. Alobwede, I. et al. CTX-M extended-spectrum β-lactamase arrives in the UK. J. Antimicrob. Chemother. 51, 470-471 (2003).
14. Tysall, L. et al. IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK. J. Antimicrob. Chemother. 49, 217-218 (2002).
15. Seppala, H. et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish study group for antimicrobial resistance. N. Engl. J. Med. 337, 441-446 (1997).
16. Austin, D. J., Kristinsson, K. G. & Anderson, R. M. The relationship between the volume of antimicrobial consumption in human communities and the frequency A resistance. Proc. Natl Acad. Sci. USA 96, 1152-1156 (1999).
17. Aarestrup, F. M. et al. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob. Agents Chemother. 45, 2054-2059 (2001 ).
18. Manninen, R., Huovinen, P. & Nissinen, A. Increasing antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland. J. Antimicrob. Chemother. 40, 387-392 (1997).
19. Chiew, Y. F., Yeo, S. F., Hall, L. M. & Livermore, D. M. Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae. J. Antimicrob. Chemother. 41, 247-251 (1998).
20. Enne, V. I., Livermore, D. M., Stephens, P. & Hall, L. M. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357, 1325-1328 (2001).
21. Kataja, J. et al. Clonal spread of group A streptococcus with the new type of erythromycin resistance. Finnish study group for antimicrobial resistance. J. Infect. Dis. 177, 786-789 (1998).
22. Soares, S., Kristinsson, K. G., Musser, J. M. & Tomasz, A. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J. Infect. Dis. 168, 158-163 (1993).
23. Bradley, S. J. et al. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J. Antimicrob. Chemother. 43, 261-266 (1999).
24. Settle, C. D., Wilcox, M. H., Fawley, W. N., Corrado, O. J. & Hawkey, P. M. Prospective study of the risk of Clostridium difficile diarrhoea elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment. Pharmacol. Ther. 12, 1217-1223 (1998).
25. Patterson, J. E., Hardin, T. C., Kelly, C. A., Garcia, R. C. & Jorgensen, J. H. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 21, 455-458 (2000).
26. Rahal, J. J. et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 280, 1233-1237 (1998).
27. Burke, J. P. Antibiotic resistance - squeezing the balloon? JAMA 280, 1270-1271 (1998).
28. Cunha, B. A. Effective antibiotic-resistance control strategies. Lancet 357, 1307-1308 (2001).
29. Mendelson, G. et al. Staphylococcus aureus carrier state among elderly residents of a long-term care facility. J. Am. Med. Dir. Assoc. 4, 125-127 (2003).
30. Wiener, J. et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281, 517-523 (1999).
31. Corkill, J. E. et al. Molecular epidemiology of endemic ciprofloxacin-resistant Neisseria gonorrhoeae in Liverpool. Int. J. STD AIDS 14, 379-385 (2003).
32. Bouchard, O. et al. Experience with an 'isolation unit' for patients infected with multi-resistant bacteria. Retrospective study of 49 patients. Presse Med. 28, 1405-1408 (1999).
33. Muto, C. A. et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect. Control Hosp. Epidemiol. 24, 362-386 (2003).
34. Kollef, M. H. & Ward, S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 113, 412-420 (1998).
35. Gillespie, S. H. Antibiotic resistance in the absence of selective pressure. Int. J. Antimicrob. Agents 17, 171-176 (2001).
36. Nagaev, I., Bjorkman, J., Andersson, D. I. & Hughes, D. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40, 433-439 (2001).
37. Maisnier-Patin, S., Berg, O. G., Liljas, L. & Andersson, D. I. Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol. Microbiol. 46, 355-366 (2002).
38. Lenski, R. E. The cost of antibiotic resistance - from the perspective of a bacterium. Ciba Found. Symp. 207, 131-140 (1997).
39. Bouma, J. E. & Lenski, R. E. Evolution of a bacteria/plasmid association. Nature 335, 351-352 (1988).
40. Rawlings, D. E. Proteic toxin-antitoxin, bacterial plasmid addiction systems and their evolution with special reference to the pas system of pTF-FC2. FEMS Microbiol. Lett. 176, 269-277 (1999).
41. Galdbart, J. O. et al. TEM-24 extended-spectrum β-lactamase-producing Enterobacter aerogenes: long-term clonal dissemination in French hospitals. Clin. Microbiol. Infect. 6 316-323 (2000).
42. Klugman, K. P. The successful clone: the vector of dissemination of resistance in Streptococcus pneumoniae. J. Antimicrob. Chemother. 50, S1-S5 (2002).
43. Arlet, G. et al. Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 β-lactamase and which were isolated in 14 French hospitals. J. Clin. Microbiol. 32, 2553-2558 (1994).
44. Johnson, A. P. et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European antimicrobial resistance surveillance system (EARSS). J. Antimicrob. Chemother. 48, 143-144 (2001).
45. Livermore, D. M. The threat from the pink corner. Ann. Med. 35, 226-234 (2003).
46. Projan, S. Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430 (2003).
47. Paterson, D. L. Recommendation for treatment of severe infections caused by Enterobacteriaceae-producing extended-spectrum β-lactamases (ESBLs). Clin. Microbiol. Infect. 6, 460-463 (2000).
48. Miller, H. I. Dying for FDA reform. Washington Times [online], (cited 20 Nov), (15 Jun 2003).
49. Sheehan, G. & Chew, N. S. Y. in Fluoroquinolone Antibiotics (eds Ronald, A. R. & Low, D. E.) 1-9 (Birkhauser-Verlag, 2003).
50. Baquero, F., Bax, R. & Phillips, I. Antibiotic clinical trials revisited. J. Antimicrob. Chemother. 46, 651-652 (2000).
51. Chopra, I., O'Neill, A. J. & Miller, K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 6, 137-145 (2003).
52. Spratt, B. G. Resistance to antibiotics mediated by target alterations. Science 264, 388-393 (1994).
53. Reacher, M. H. et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 320, 213-216 (2000).